Last reviewed · How we verify
Symbicort Turbuhaler 160/4.5
Symbicort combines a long-acting beta-2 agonist (formoterol) and an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation.
Symbicort combines a long-acting beta-2 agonist (formoterol) and an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Symbicort Turbuhaler 160/4.5 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) |
| Target | Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Budesonide is a corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Formoterol is a long-acting beta-2 agonist that binds to beta-2 adrenergic receptors on bronchial smooth muscle, causing relaxation and bronchodilation. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained asthma and COPD control.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness
- Muscle cramps
Key clinical trials
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (PHASE3)
- Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy (PHASE4)
- Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma (PHASE3)
- Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER® (PHASE3)
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Mechanism(s) of Airflow Limitation During Exacerbation of Asthma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symbicort Turbuhaler 160/4.5 CI brief — competitive landscape report
- Symbicort Turbuhaler 160/4.5 updates RSS · CI watch RSS
- AstraZeneca portfolio CI